Using assets acquired from the purchase of US clinical stage viral vaccine development firm Profectus Biosciences, Inc., Aurobindo Pharma Limited has entered the fray for a COVID-19 vaccine.
Aurobindo Enters Fray For COVID-19 Vaccine
Generic to Teva’s Qvar Filed?
Building on assets acquired from Profectus BioSciences, Aurobindo Pharma has thrown its hat in the ring for a COVID-19 vaccine. Amid speculation it has filed for a generic to Teva’s asthma product Qvar in the US, the company hopes a healthy product pipeline will help it maintain growth despite pandemic-led challenges.
More from Business
• By
As the PDUFA date for the UK major’s IL-5 inhibitor draws close.
• By
CEO Vas Narasimhan urged European governments to spend more to support drug innovation during Novartis's first-quarter results call.
• By
Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.
• By
BridgeBio reported $36.7m in Q1 2025 sales of its ATTR-CM drug Attruby, tripling consensus forecasts. Vyndaquel-maker Pfizer acknowledged the product’s impact during the quarter.
More from Scrip
• By
BridgeBio reported $36.7m in Q1 2025 sales of its ATTR-CM drug Attruby, tripling consensus forecasts. Vyndaquel-maker Pfizer acknowledged the product’s impact during the quarter.
• By
The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.
• By
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.